person · Reporting owner

Stein Jeffrey

Disclosed activity across 3 companies

Tapewire entity: 36795
SEC CIK: 0001478831

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IDEAYA Biosciences, Inc.IDYA · Entity 4069	Director	June 16, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IDEAYA Biosciences, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16	Direct	20,000	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cidara Therapeutics, Inc.

Report date January 07, 2026 · Filed January 08, 2026

Section 16 reporting ended · disclosed 2026-01-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-01-07 transaction · row 1 1 source row Row 1 · 2026-01-07 · Disposition to issuer · Disposed 5,763 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes.
Common StockSEC Table I · non-derivative	IndirectBy son	Reported balance After 2026-01-07 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-01-07 · Disposition to issuer · Disposed 2,379 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes.
Common StockSEC Table I · non-derivative	IndirectBy trust	Reported balance After 2026-01-07 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-01-07 · Disposition to issuer · Disposed 67,498 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.80 · Expires 2026-03-15	Direct	Reported balance After 2026-01-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-07 · Disposition to issuer · Disposed 7,949 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.00 · Expires 2027-03-30	Direct	Reported balance After 2026-01-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-07 · Disposition to issuer · Disposed 11,000 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $80.00 · Expires 2028-03-28	Direct	Reported balance After 2026-01-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-07 · Disposition to issuer · Disposed 11,749 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.20 · Expires 2029-03-20	Direct	Reported balance After 2026-01-07 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-07 · Disposition to issuer · Disposed 13,249 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.60 · Expires 2030-03-18	Direct	Reported balance After 2026-01-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-07 · Disposition to issuer · Disposed 16,499 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.00 · Expires 2031-03-16	Direct	Reported balance After 2026-01-07 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-01-07 · Disposition to issuer · Disposed 26,249 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.65 · Expires 2032-03-30	Direct	Reported balance After 2026-01-07 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-01-07 · Disposition to issuer · Disposed 16,499 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.20 · Expires 2033-03-26	Direct	Reported balance After 2026-01-07 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-01-07 · Disposition to issuer · Disposed 27,174 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.70 · Expires 2034-03-14	Direct	Reported balance After 2026-01-07 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-01-07 · Disposition to issuer · Disposed 51,999 · Balance 0 F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.75 · Expires 2034-09-29	Direct	Reported balance After 2026-01-07 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-01-07 · Disposition to issuer · Disposed 560,888 · Balance 0 F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.54 · Expires 2035-03-30	Direct	Reported balance After 2026-01-07 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-01-07 · Disposition to issuer · Disposed 275,000 · Balance 0 F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2]

F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]

F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes.

F4: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.

F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.

Paratek Pharmaceuticals, Inc.

Report date September 21, 2023 · Filed September 21, 2023

Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2023-09-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-09-21 · Disposition to issuer · Disposed 48,625 · Balance 20,000 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. Row 2 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2031-02-18	Direct	Reported balance After 2023-09-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2030-02-19	Direct	Reported balance After 2023-09-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.23 · Expires 2029-02-26	Direct	Reported balance After 2023-09-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2028-02-14	Direct	Reported balance After 2023-09-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.10 · Expires 2027-02-01	Direct	Reported balance After 2023-09-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-21 · Disposition to issuer · Disposed 6,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2026-02-03	Direct	Reported balance After 2023-09-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-09-21 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.07 · Expires 2025-02-03	Direct	Reported balance After 2023-09-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,

F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.

F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 31, 2022 Filed Apr 4, 2022 21:09 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantCommon Stock	408,742	$0.00	$0.00	Disclosure SEC source: 0001610618-22-000023 · wf-form4_164910656863339.xml · nonDerivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,620 F2 · shares: Represents RSUs granted on March 31, 2022. All RSUs are fully vested as of the grant date. Read SEC document
March 31, 2022 Filed Apr 4, 2022 21:09 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantCommon Stock	165,000	$0.00	$0.00	Disclosure SEC source: 0001610618-22-000023 · wf-form4_164910656863339.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,878 F1 · shares: Represents time-based Restricted Stock Units (RSUs) granted on March 31, 2022. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2023, 2024, and 2025, subject to continuous service through each such vesting date. Read SEC document
February 16, 2022 Filed Feb 18, 2022 17:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0000904454-22-000173 · edgar.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,625 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 16, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
December 31, 2021 Filed Jan 8, 2026 01:12 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GiftCommon Stock	937	$0.00	$0.00	Disclosure SEC source: 0001478831-26-000004 · wk-form4_1767834742.xml · nonDerivative · entry 12 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By son Disclosed balance after: 2,379 F8 · kind: This transaction involved a gift of securities by the Reporting Person to his sons, one of which is economically dependent on the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares held by his independent son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his independent son's shares for purposes of Section 16 or for any other purpose. F2 · shares: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document
December 31, 2021 Filed Jan 8, 2026 01:12 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GiftCommon Stock	1,873	$0.00	$0.00	Disclosure SEC source: 0001478831-26-000004 · wk-form4_1767834742.xml · nonDerivative · entry 11 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 67,498 F8 · kind: This transaction involved a gift of securities by the Reporting Person to his sons, one of which is economically dependent on the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares held by his independent son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his independent son's shares for purposes of Section 16 or for any other purpose. F2 · shares: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document
December 29, 2021 Filed Jan 8, 2022 01:24 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	Exercise / conversionRestricted Stock Unit · Derivative	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002603 · doc4.xml · derivative · entry 4 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer. F4 · derivative.exercise_date: On January 31, 2019, the Reporting Person was granted restricted stock units totaling 60,000 shares subject to vesting upon the achievement of various milestones. Read SEC document
December 29, 2021 Filed Jan 8, 2022 01:24 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	Exercise / conversionCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002603 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person was previously granted restricted stock units to vest upon the achievement of certain milestone events that occurred on December 29, 2021. F2 · balance_after: Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 19, 2021. Read SEC document
November 12, 2021 Filed Nov 15, 2021 23:41 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	50,000	$1.59	$79,530.00	Disclosure SEC source: 0001610618-21-000108 · wf-form4_163701966996163.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,878 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document
August 19, 2021 Filed Aug 19, 2021 20:24 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	10,000	$1.79	$17,871.00	Disclosure SEC source: 0001209191-21-052546 · doc4.xml · nonDerivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,878 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7850 to $1.7899, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document
August 18, 2021 Filed Aug 19, 2021 20:24 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	40,000	$1.72	$68,884.00	Disclosure SEC source: 0001209191-21-052546 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,878 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6990 to $1.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F2 · balance_after: Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2021. Read SEC document
June 10, 2021 Filed Jun 16, 2021 21:05 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $21.66	$0.00	Disclosure SEC source: 0001567619-21-012207 · doc1.xml · derivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
March 31, 2021 Filed Apr 5, 2021 19:00 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001610618-21-000028 · wf-form4_161764918481353.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,878 F1 · shares: The reporting person was previously granted a performance restricted stock unit (PRSU) to vest upon the achievement of a certain milestone event that occurred on 3/31/21. Read SEC document
March 17, 2021 Filed Mar 20, 2021 01:19 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantEmployee Stock Option (right to buy) · Derivative	525,000	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001610618-21-000026 · wf-form4_161620315413253.xml · derivative · entry 4 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2031-03-16 F4 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021. Read SEC document
February 18, 2021 Filed Feb 22, 2021 18:46 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	7,000	$0.00 Strike: $7.61	$0.00	Disclosure SEC source: 0000904454-21-000238 · edgar.xml · derivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-02-18 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 18, 2021, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 18, 2021 Filed Feb 22, 2021 18:46 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	9,000	$0.00	$0.00	Disclosure SEC source: 0000904454-21-000238 · edgar.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,625 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 18, 2021, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
December 10, 2020 Filed Jan 8, 2026 01:12 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	OtherCommon Stock	658	$0.00	$0.00	Disclosure SEC source: 0001478831-26-000004 · wk-form4_1767834742.xml · nonDerivative · entry 10 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By son Disclosed balance after: 1,442 F7 · kind: Form 4 originally filed on March 19, 2021 erroneously reported a 26,300 share gift as a holding rather than a transaction and further overstated the holdings received by son by 13,150 shares. F2 · shares: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document
November 10, 2020 Filed Nov 12, 2020 11:00 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	50,000	$2.00	$100,015.00	Disclosure SEC source: 0001209191-20-057807 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,878 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.99 to $2.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F2 · balance_after: Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2020. Read SEC document
November 10, 2020 Filed Jan 8, 2026 01:12 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	2,500	$40.01	$100,015.00	Disclosure SEC source: 0001478831-26-000004 · wk-form4_1767834742.xml · nonDerivative · entry 9 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 69,371 F6 · kind: Form 4 originally filed on November 10, 2020 erroneously reported the securities as purchased by Reporting Person rather than by trust. F2 · shares: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2 · price: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document
November 10, 2020 Filed Jan 8, 2026 01:12 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	OtherCommon Stock	2,500	$40.01	$100,015.00	Disclosure SEC source: 0001478831-26-000004 · wk-form4_1767834742.xml · nonDerivative · entry 8 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,763 F6 · kind: Form 4 originally filed on November 10, 2020 erroneously reported the securities as purchased by Reporting Person rather than by trust. F2 · shares: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2 · price: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document
June 16, 2020 Filed Jun 18, 2020 20:41 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $12.84	$0.00	Disclosure SEC source: 0001567619-20-012374 · doc1.xml · derivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
March 19, 2020 Filed Mar 23, 2020 23:17 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantEmployee Stock Option (right to buy) · Derivative	330,000	$0.00 Strike: $1.98	$0.00	Disclosure SEC source: 0001209191-20-020751 · doc4.xml · derivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2030-03-18 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020. Read SEC document
February 19, 2020 Filed Feb 21, 2020 21:33 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	7,000	$0.00 Strike: $3.51	$0.00	Disclosure SEC source: 0000904454-20-000240 · edgar.xml · derivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-02-19 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 19, 2020, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 19, 2020 Filed Feb 21, 2020 21:33 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	9,000	$0.00	$0.00	Disclosure SEC source: 0000904454-20-000240 · edgar.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,625 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 19, 2020, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
January 29, 2020 Filed Jan 31, 2020 01:50 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	OtherSubscription Rights (right to buy) · Derivative	32,283	$0.00 Strike: $2.51	$0.00	Disclosure SEC source: 0001209191-20-005705 · doc4.xml · derivative · entry 5 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 32,283 shares Expires 2020-02-10 F1 · kind: Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020. Read SEC document
January 29, 2020 Filed Jan 31, 2020 01:50 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	OtherSubscription Rights (right to buy) · Derivative	7,558	$0.00 Strike: $2.51	$0.00	Disclosure SEC source: 0001209191-20-005705 · doc4.xml · derivative · entry 4 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,558 shares Expires 2020-02-10 F1 · kind: Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020. Read SEC document
January 29, 2020 Filed Jan 31, 2020 01:50 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	OtherCommon Stock	32,283	$2.51	$81,030.33	Disclosure SEC source: 0001209191-20-005705 · doc4.xml · nonDerivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 257,902 F1 · kind: Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020. Read SEC document
January 29, 2020 Filed Jan 31, 2020 01:50 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	OtherCommon Stock	7,558	$2.51	$18,970.58	Disclosure SEC source: 0001209191-20-005705 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,878 F1 · kind: Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020. F2 · balance_after: Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2019. Read SEC document
September 24, 2019 Filed Sep 27, 2019 01:23 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	52,500	$1.91	$100,101.75	Disclosure SEC source: 0001209191-19-050923 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 225,619 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.84 to $1.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document
September 24, 2019 Filed Dec 20, 2019 00:07 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	1,250	$0.00 Strike: $9.15	$0.00	Disclosure SEC source: 0001567619-19-023455 · doc1.xml · derivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2029-09-23 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
September 12, 2019 Filed Sep 16, 2019 21:41 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	Exercise / conversionRestricted Stock Unit · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-049694 · doc4.xml · derivative · entry 4 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · shares: This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19. F4 · derivative.exercise_date: A portion of the shares vest upon the achievement of various clinical and corporate milestones. F4 · derivative.expiration_date: A portion of the shares vest upon the achievement of various clinical and corporate milestones. Read SEC document
September 12, 2019 Filed Sep 16, 2019 21:41 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-049694 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,320 F1 · shares: This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19. F2 · balance_after: Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2019. Read SEC document
March 21, 2019 Filed Mar 22, 2019 20:49 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantEmployee Stock Option (right to buy) · Derivative	265,000	$0.00 Strike: $2.61	$0.00	Disclosure SEC source: 0001209191-19-021009 · doc4.xml · derivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2029-03-20 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 21, 2019. Read SEC document
February 26, 2019 Filed Feb 28, 2019 19:48 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $7.23	$0.00	Disclosure SEC source: 0000904454-19-000291 · edgar.xml · derivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-26 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 26, 2019, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 26, 2019 Filed Feb 28, 2019 19:48 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	7,500	$0.00	$0.00	Disclosure SEC source: 0000904454-19-000291 · edgar.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,625 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 26, 2019, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
February 26, 2019 Filed Mar 13, 2019 16:54 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GiftCommon Stock	10,670	$0.00	$0.00	Disclosure SEC source: 0001209191-19-019068 · doc4.xml · nonDerivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 15,709 F1 · kind: This transaction involved a gift of securities by the reporting person to his sons, one of which is economically dependent on the reporting person. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
February 26, 2019 Filed Mar 13, 2019 16:54 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GiftCommon Stock	21,340	$0.00	$0.00	Disclosure SEC source: 0001209191-19-019068 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 173,119 F1 · kind: This transaction involved a gift of securities by the reporting person to his sons, one of which is economically dependent on the reporting person. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
February 15, 2019 Filed Feb 20, 2019 16:45 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	3,375	$7.14	$24,097.50	Disclosure SEC source: 0000904454-19-000256 · edgar.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $7.09 to $7.20. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document
January 31, 2019 Filed Feb 2, 2019 00:05 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	Exercise / conversionRestricted Stock Unit · Derivative	60,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-006610 · doc4.xml · derivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2022-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares shall vest upon the achievement of various clinical and corporate milestones. Read SEC document
November 29, 2018 Filed Dec 5, 2018 00:08 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GiftCommon Stock	4,619	$0.00	$0.00	Disclosure SEC source: 0001209191-18-061058 · doc4.xml · nonDerivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 5,039 F1 · kind: This transaction involved a gift of securities by the reporting person to his sons, one of which is economically dependent on the reporting person. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
November 29, 2018 Filed Dec 5, 2018 00:08 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GiftCommon Stock	9,238	$0.00	$0.00	Disclosure SEC source: 0001209191-18-061058 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 194,459 F1 · kind: This transaction involved a gift of securities by the reporting person to his sons, one of which is economically dependent on the reporting person. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
May 23, 2018 Filed May 24, 2018 21:16 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantWarrant (right to buy) · Derivative	250,000	$0.13 Strike: $6.81	$31,250.00	Disclosure SEC source: 0001209191-18-033073 · doc4.xml · derivative · entry 4 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F3 · derivative.expiration_date: The Warrants will expire upon the earliest of (i) May 23, 2023, (ii) the date that the holder of such Warrant transfers or sells any of the shares of Common Stock purchased by such holder in the first closing of the offering (i.e. May 23, 2018), if such transfer or sale occurs prior to the date that is 120 calendar days following May 23, 2018, (iii) the taking of any short position on the Common Stock by the holder of such Warrant prior to the completion of the second closing of the offering, to be determined, and (iv) the failure by the holder of such Warrant to purchase its pro rata allocation of shares of Common Stock in the second closing of the offering, to be determined. Read SEC document
May 23, 2018 Filed May 24, 2018 21:16 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	212,766	$4.70	$1,000,000.20	Disclosure SEC source: 0001209191-18-033073 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,320 F1 · shares: Shares were purchased in a registered direct offering pursuant to a Subscription Agreement dated May 21, 2018. F2 · balance_after: Includes 3,703 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 18, 2018. Read SEC document
March 29, 2018 Filed Apr 2, 2018 23:35 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	GrantEmployee Stock Option (right to buy) · Derivative	235,000	$0.00 Strike: $4.00	$0.00	Disclosure SEC source: 0001209191-18-022588 · doc4.xml · derivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2028-03-28 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 29, 2018. Read SEC document
February 14, 2018 Filed Feb 16, 2018 17:27 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $14.15	$0.00	Disclosure SEC source: 0000904454-18-000205 · edgar.xml · derivative · entry 2 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 14, 2018, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 14, 2018 Filed Feb 16, 2018 17:27 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	7,500	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000205 · edgar.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 14, 2018, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
September 12, 2017 Filed Sep 12, 2017 21:49 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	7,350	$6.79	$49,906.50	Disclosure SEC source: 0001209191-17-052467 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,851 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.75 to $6.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document
September 12, 2017 Filed Jan 8, 2026 01:12 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	367	$135.80	$49,838.60	Disclosure SEC source: 0001478831-26-000004 · wk-form4_1767834742.xml · nonDerivative · entry 7 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 66,871 F5 · kind: Form 4 originally filed on September 12, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust. F2 · shares: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2 · price: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document
September 12, 2017 Filed Jan 8, 2026 01:12 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	OtherCommon Stock	367	$135.80	$49,838.60	Disclosure SEC source: 0001478831-26-000004 · wk-form4_1767834742.xml · nonDerivative · entry 6 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,263 F5 · kind: Form 4 originally filed on September 12, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust. F2 · shares: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2 · price: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document
June 05, 2017 Filed Jun 7, 2017 20:45 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	15,000	$5.95	$89,211.00	Disclosure SEC source: 0001209191-17-038321 · doc4.xml · nonDerivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,501 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.88 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F2 · balance_after: Includes 2,305 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 19, 2017. Read SEC document
June 05, 2017 Filed Jan 8, 2026 01:12 UTC	Cidara Therapeutics, Inc. CDTX · Entity 69639	PurchaseCommon Stock	750	$118.95	$89,211.00	Disclosure SEC source: 0001478831-26-000004 · wk-form4_1767834742.xml · nonDerivative · entry 5 Stein Jeffrey · CIK 0001478831 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 66,504 F4 · kind: Form 4 originally filed on June 7, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust. F2 · shares: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F2 · price: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.